Vasohibin-1 suppresses colon cancer

Shuai Liu; Bing Han; Qunyuan Zhang; Jie Dou; Fang Wang; Wenli Lin; Yuping Sun; Guangyong Peng

doi:10.18632/oncotarget.3493

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Vasohibin-1 suppresses colon cancer

Shuai Liu, Bing Han, Qunyuan Zhang, Jie Dou, Fang Wang, Wenli Lin, Yuping Sun and Guangyong Peng _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:7880-7898. https://doi.org/10.18632/oncotarget.3493

Metrics: PDF 3282 views | HTML 2760 views | ?

Abstract

Shuai Liu1,2, Bing Han2,3, Qunyuan Zhang4, Jie Dou2, Fang Wang2, Wenli Lin1, Yuping Sun1 and Guangyong Peng2

1 Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, P. R. China

2 Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, USA

3 Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, P.R. China

4 Department of Genetics, Washington University School of Medicine, Saint Louis, MO, USA

Correspondence to:

Yuping Sun, email:

Guangyong Peng, email:

Keywords: VASH1, Colon cancer, Angiogenesis, Tumor suppressor, Metastasis

Received: December 10, 2014 Accepted: February 04, 2015 Published: March 08, 2015

Abstract

Vasohibin-1 (VASH1) is an endogenous angiogenesis inhibitor.However, the clinical relevance of VASH1 in colon cancer and its regulations on cancer angiogenesis and cancer cell biological characteristics are still unknown. Here we showed that stromal VASH1 levels were negatively correlated with tumor size, advanced clinical stage and distant metastases in colon cancer patients. Overexpression of VASH1 in colon cancer cells induced apoptosis and senescence, inhibiting cancer cell growth and colony formation in vitro and tumor growth in vivo. In addition, knockdown of VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and enhanced tumorigenesis and metastasis in vivo.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3493

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Vasohibin-1 suppresses colon cancer

Abstract